ArticlePLoS pathogens2025
Kaposi sarcoma-associated herpesvirus cooperates with Epstein-Barr virus to co-transform a small set of human B cells oncogenically.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extracavitary Primary Effusion Lymphoma: Diagnostic Challenges and Differential Diagnosis in a Resource-Constrained South African Setting.International journal of surgical pathology · 2026Article
- LANA-specific CD4Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
KSHV has not been found to transform human B cells alone. We show now it infects both peripheral and tonsillar B cells inefficiently and cooperates with EBV to co-transform a similar, small fraction of cells from both sources. These cells yield immortalized progeny, one hallmark of transformation, and depend on both viruses for their continued growth. The cells secrete multiple cytokines that support their paracrine growth and express viral genes that mediate expression of these cytokines. The co-transformed cells grow preferentially as tumors in the peritoneal cavities of NSG mice outgrowing B cells transformed only by EBV. The levels of EBV genes expressed in co-transformed cells decrease during growth in vitro and more so during tumor growth in vivo while those of KSHV increase, mirroring that found In Primary Effusion Lymphoma (PEL) derived cell lines. The expression of cellular genes changes too, to reflect that of PEL biopsies. Both KSHV and EBV oncogenes are expressed in the co-transformed cells that regulate the gene signature of PELs, making these co-transformed cells a tractable model with which to understand this unique lymphoma associated with these two tumor viruses. Studies of this model will also illuminate the individual contributions of each virus to the many cancers they cause.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.